ProMIS Neurosciences Inc., a clinical-stage biotechnology firm focused on developing therapeutic antibodies for neurodegenerative diseases, has filed a prospectus with the U.S. Securities and Exchange Commission regarding a registered direct offering. The company plans to raise approximately $0.8 million from an existing healthcare-focused institutional investor. The funds will be used to advance the clinical development of PMN310, ProMIS's leading therapeutic candidate, as well as for working capital and general corporate purposes. The offering involves the issuance and sale of pre-funded warrants to purchase 984,736 common shares at a price of $0.8124 per share. These warrants are exercisable at a nominal price of $0.0001 per share and can be activated at any time until fully exercised. The closing of the offering is anticipated on or around July 24, 2025, pending customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.